Olympus Corp. shares fall sharply after the US Food and Drug Administration issues a warning letter to the Japanese medical device maker. Multiple outlets report the decline is the company’s biggest one-day drop since at least 2011, with the stock moving toward a 12-week low.
The FDA warning letter follows inspections conducted at six of Olympus’ facilities. The reports focus on concerns related to the company’s quality systems, which the FDA flags in its letter. The reaction in markets suggests investors are reassessing the potential impact on compliance, operations, and any required corrective actions at the affected sites.
While coverage centers on the same FDA action and the number of facilities involved, the outlets differ slightly in emphasis: one highlights the magnitude of the stock move, while others stress the quality-systems issue and the specific FDA warning-letter context. All accounts attribute the large drop to the FDA notification rather than to company guidance or unrelated operational updates.
